Symbols

BIOA

BioAge Labs·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BIOA

Bioage Labs, Inc.

A biotech company focused on assessing and optimizing biological age

Industry

Pharmaceutical

Established Date

04/01/2015

Listing Date

09/26/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bioagelabs.com

Security Type

Common stock

Office address

5885 Hollis Street Suite 370 Emeryville CA 94608

Business

Introduction

BioAge Labs, Inc., was incorporated in Delaware on April 1, 2015. The company is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets allow them to identify promising targets based on insights into the molecular changes that drive aging.

Company Financials

EPS

BIOA has released its 2025 Q4 earnings. EPS was reported at -0.72, versus the expected -0.74, beating expectations. The chart below visualizes how BIOA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIOA has released its 2025 Q4 earnings report, with revenue of 3.08M, reflecting a YoY change of NaN%, and net profit of -25.94M, showing a YoY change of -22.78%. The Sankey diagram below clearly presents BIOA's revenue sources and cost distribution.